AXIM Biotechnologies, Inc. AXIM OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

22/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

AXIM Biotechnologies, Inc. (AXIM) reported total assets of $3.45M and total liabilities of $13.87M for fiscal year 2024, resulting in total equity of $-10.42M.

The company held $245.00 in cash and short-term investments. Total debt stood at $6.64M, with net debt of $6.64M. The Debt-to-Equity (D/E) ratio was -0.64 (conservative).

Current ratio is 0, which may signal tight short-term liquidity. Interest coverage is -2.8x (weak).

Criteria supported by this page:

HEALTH (0/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
MOAT (0/100) — Total assets $3.45M and equity $-10.42M support the company's competitive scale

Overall SharesGrow Score: 21/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

22/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

0/100

→ Income

✓

GROWTH

100/100

→ Income

✗

INCOME

10/100

→ Income

AXIM Biotechnologies, Inc. Balance Sheet History

Metric	FY2024	FY2023	FY2022	FY2021
Total Assets	$3.45M	$4.12M	$4.21M	$5.32M
Total Liabilities	$13.87M	$11.78M	$9.04M	$7.66M
Total Debt	$6.64M	$5.89M	$5.66M	$6.72M
Cash & Investments	$245.00	$156.46K	$47.28K	$452.96K
Total Stockholders Equity	$-10.42M	$-7.66M	$-4.83M	$-2.34M